Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012647Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 26 abril 2017see what's new
- Tipo:
-
- Prognosis
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Vías respiratorias
- Copyright:
-
- Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Coordinating the review: YHK
Drafting protocol and review: YHK, NG, CM, AH
Designing search strategies: YHK, Cochrane Airways Group Information Specialist (Elizabeth Stovold)
Data collection for the review: YHK, YN
Data analysis: YHK, AH
Data interpretation: YHK, NG, CM, AH
Sources of support
Internal sources
-
Department of Respiratory and Sleep Medicine, Austin Health, Australia.
Support to YHK, NG and CM
-
Institute for Breathing and Sleep, Australia.
Support to YHK, YN, NG, CM and AH
-
School of Allied Health, La Trobe University, Australia.
Support to AH
External sources
-
National Health and Medical Research Council, Australia.
YHK is supported by the National Health and Medical Research Council Postgraduate Scholarship.
Declarations of interest
YHK: None known
YN: None known
NG: None known
AH: None known
CM has received personal fees for participation in advisory boards for Pfizer and Novartis; has participated in advisory board for Astra Zeneca (no fee); has received speakers fees from GSK and Novartis; and has received in‐kind support for a research project from Air Liquide.
Acknowledgements
Haydn Walters and Katriana Williams were the Editors for this review and commented critically on the review.
This work was supported by the Cochrane Prognosis Methods Group for the development of the study protocol.
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2017 Apr 26 | Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies | Protocol | Yet H Khor, Yvonne Ng, Nicole SL Goh, Christine F McDonald, Anne E Holland | |
| Criteria | High risk of bias | Low risk of bias | Unclear/other |
| Sample | Clinical | Population | Unclear |
| Recruitment | Retrospective | Prospective | Unclear |
| Selection criteria for participants | No | Yes | Unclear |
| Baseline characteristics of participants | No | Yes | Unclear |
| Follow‐up percentage (if RCT) | < 80% | ≥ 80% | Unclear |
| Not applicable | |||
| Follow‐up duration | < 1 year | ≥ 1 year | Unclear |
| Reason lost to follow‐up | No | Yes | Unclear |
| Timing of diagnosis | At the conclusion of the study | At baseline or before recruitment to study | Unclear |
| Blinding | Not blinded | Blinding adequate | Unclear |
| Outcome described a priori | No | Yes | Unclear |
| Intention‐to‐treat analysis (if RCT) | No | Yes | Unclear |
| Not applicable | |||
| Adequate description of statistical analysis | No | Yes | Unclear |
